All In Biotech

Drug Trial Radar · NCT03275415

Intratracheal Budesonide/Surfactant Prevents BPD

Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study

Last checked: Nov 20, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

310

Actual

Start

Jul 1, 2019

Primary completion

Jun 30, 2022

Study completion Jun 30, 2022

Sponsor

Lead sponsor
Taipei Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Taipei Medical University Hospital; National Taiwan University Hospital; Taipei Veterans General Hospital, Taiwan; Mackay Memorial Hospital; Chang Gung Memorial Hospital; China Medical University Hospital; Seventh Medical Center of PLA General Hospital; Guangzhou Women and Children's Medical Center; Taichung Veterans General Hospital
First posted
Sep 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 30 minutes, up to 4 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind study includes: 1) birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires resuscitation 3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 ≥ 0.30, pressure \> 5cmH2O b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg. Exclusion criteria: 1) lethal cardiopulmonary status 2) severe congenital anomalies. Given the COVID19 pandemics, the recruitment became difficult. Under the consideration of scientific and practical consideration, we therefore determine to have a sample of 300, (150 in each group), fulfill the criteria of type I error 0.05, type II error 0.10, power 90% and with an expectation of 30 % improvement of primary outcome (from 60 % in control group to 40 % in the intervention group as original presumed).Appropriate amount of placebo will be used as it does not affect the biophysical property of curosurf (PAS abstract 2017 San Francisco). Primary outcome of study is death or BPD defined by NICHD criteria. Follow up study of neuromotor and cognitive function and pulmonary states will be done at 1-2 years of corrected age.

Conditions

  • Respiratory Distress Syndrome
  • Bronchopulmonary Dysplasia

Interventions

  • budesonideDrug

    Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD

  • SalineDrug

    Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of death or BPDTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.